WALTHAM, Mass., April 10, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), today reported publication of results from a clinical study of Quell® in the Journal of Pain Research. The paper is titled “Effectiveness of fixed-site high-frequency transcutaneous electrical nerve stimulation in chronic pain: a large-scale, observational study.” It is available for download at: Journal of Pain Research.
Key study findings included:
- Quell was used an average of 35 hours per week by the study subjects.
- Study subjects reported statistically and clinically significant improvement in all pain outcomes.
- All pain outcomes exhibited a strong dose-response relationship.
- About 60% of subjects with high device utilization reported a large (at least 2 point) improvement in pain interference with activity or mood.
The design was a retrospective, observational cohort study that examined changes in chronic pain outcomes following 60 days of Quell use. The study data were obtained from Quell users who consented to upload their device usage and clinical data to the Quell Health Cloud and who rated their pain at baseline (before starting Quell therapy) and 60 days later. The primary outcome measures were changes in pain intensity and pain interference with sleep, activity, and mood on an 11-point numerical rating scale. Dose–response associations were evaluated by stratifying subjects into low (≤30 days), intermediate (31–56 days), and high (≥57 days) utilization.
The study population consisted of 713 subjects. The average age was 55 years and 52% were female. Most subjects had chronic pain for over 3 years. The subjects had 5 sites of pain on average and complex medical histories with arthritis (62%), prior low back injury (41%), herniated disc (30%), spinal stenosis (29%) and fibromyalgia (26%) as the most common. At baseline, 47% of the subjects had severe pain.
"We are pleased that the results of this large, real-world study of Quell effectiveness has been published. The findings confirm that Quell provides valuable incremental pain relief to many individuals with chronic pain," said Shai N. Gozani, M.D., Ph.D. President and CEO of NeuroMetrix, Inc. "Importantly, this is the first study using data collected in the Quell Health Cloud that has been peer reviewed and published in a pain journal. We believe that our ability to leverage the Quell Health Cloud to conduct sophisticated, large scale scientific and clinical research is a substantial long term competitive advantage.”
About Quell
Quell is an advanced, wearable technology for treating chronic pain. It can be worn during the day while active and at night while sleeping. Quell is drug-free and has been cleared by the FDA for treatment of chronic pain without a prescription. Quell users can personalize and manage therapy discreetly via the Quell app. Quell also offers health tracking relevant to chronic pain sufferers including pain, sleep, activity, and gait. Quell users can synchronize their data with the Quell Health Cloud, which provides customized feedback and powers one of the world’s largest chronic pain databases. Quell is available online and through select retailers. Visit QuellRelief.com for more information.
About NeuroMetrix
NeuroMetrix is an innovation driven healthcare company combining neurostimulation and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The company's lead product is Quell, an over-the-counter wearable therapeutic device for chronic pain. The company also markets DPNCheck®, a rapid point-of-care test for diabetic neuropathy, which is the most common long-term complication of Type 2 diabetes. For more
information, please visit NeuroMetrix.com.
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer
neurometrix.ir@neurometrix.com
Source: NeuroMetrix, Inc.